Tattoli Mark Damian 4
4 · Core Laboratories Inc. /DE/ · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Core Laboratories (CLB) SVP Mark Tattoli Receives 33,490-Share Award
What Happened
Mark Damian Tattoli, SVP, General Counsel & Secretary of Core Laboratories (CLB), was granted a derivative award of 33,490 shares on February 12, 2026 (reported on Form 4). The award was recorded at $0.00 per share (a performance-based equity grant rather than an open-market purchase or sale), so there is no immediate cash exchanged — future vesting and number of shares delivered depend on performance metrics.
Key Details
- Transaction date and type: 2026-02-12 — Grant/Award (derivative), reported 2026-02-17. Filing appears timely.
- Reported price: $0.00 per share (award).
- Shares in this grant: 33,490 shares (maximum referenced as 100% of the award; actual vesting can vary).
- Shares owned after transaction: not specified in the excerpt of the filing provided.
- Footnotes / vesting conditions: see below (summarized).
- Filing timeliness: filed Feb 17, 2026; given the Feb 16 holiday, this filing appears within the required SEC window.
Context (simple explanation of the award and vesting)
- The award is a three-year performance-based grant covering the period Jan 1, 2026–Dec 31, 2028. Vesting on Dec 31, 2028 depends on Core Labs’ Return on Invested Capital (ROIC) vs. a Bloomberg Peer Group: 50% vests at the 35th percentile, 100% at the 55th percentile, and up to 175% if at/above the 85th percentile, with straight-line interpolation between tiers.
- An additional adjustment: any portion vesting above 100% (up to the 175% maximum) would be reduced by half if absolute total shareholder return (TSR) over the period is negative.
- The award survives termination for death, disability, termination by the company without cause, or retirement at/after age 62; in those cases vesting (if any) still occurs on Dec 31, 2028.
- Practical takeaway: this is a performance-contingent equity grant, not an immediate purchase or sale; its ultimate value to the insider depends on future company performance.
Insider Transaction Report
Form 4
Tattoli Mark Damian
SVP, Gen Counsel & Secretary
Transactions
- Award
Performance Shares
[F1][F2]2026-02-12+33,490→ 33,490 totalExercise: $0.00→ Common Stock (33,490 underlying)
Footnotes (2)
- [F1]This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.
- [F2]The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.
Signature
/s/ Mark D. Tattoli|2026-02-17